摘要
背景:上皮间质转化(EMT)是肿瘤转移的主要决定因素,与TGF-β1密切相关。细胞内蛋白质,包括E.钙粘蛋白,N.钙粘蛋白和波形蛋白与EMT直接相关,影响细胞迁移和粘附;另一方面,非肌肉肌球蛋白(NM)在胞质分裂,迁移和粘附中具有核心作用。目的:通过调控非肌肉肌球蛋白II-A(NMII-A)及其与己糖胺生物合成途径(HBP)的相互作用,探讨EMT与转移与TGF-β1的关系。 方法:蛋白质表达的变化通过免疫印迹和免疫荧光染色进行评估,而通过qRT-PCR评估转录水平的变化。 EMT通过表型分析,伤口愈合,增殖和transwell迁移实验体外评估,而在BALB / c裸鼠体内研究肺原位和尾静脉转移模型。 结果:我们证明TGF-β1对JNK / P38 / PI3K的调节导致了NMII-A的下调,促进了EMT和肺癌的转移。 NMII-A的这种下调表达反过来上调核心2 N-乙酰葡糖胺基转移酶粘蛋白型(C2GnT-M)的表达,并进一步促进了N-乙酰葡糖胺转移酶(GnT)-V和-III的上调和下调;此外,NMII-A K.D细胞在体内显示出向脑部迁移3倍的倾向。 结论:本研究报道了NMII-A通过上调C2GnT-M,GnT-V和GnT-III的下调表达负调节EMT和转移的新途径。这些肺癌的发现可能还需要研究其他癌症类型。
关键词: NMII-A,EMT,C2GnT-M,GnT-III,GnT-V,GlcNAc,HBP,肺癌转移。
图形摘要
Current Cancer Drug Targets
Title:TGF-β1 Causes EMT by Regulating N-Acetyl Glucosaminyl Transferases via Downregulation of Non Muscle Myosin II-A through JNK/P38/PI3K Pathway in Lung Cancer
Volume: 18 Issue: 2
关键词: NMII-A,EMT,C2GnT-M,GnT-III,GnT-V,GlcNAc,HBP,肺癌转移。
摘要: Background: Epithelial to mesenchymal transition (EMT) is a major determinant of cancer metastasis and is closely linked with TGF-β1. Intracellular proteins, including E. Cadherin, N. Cadherin and Vimentin are directly related to EMT that affect cell migration and adhesion; on the other hand, non muscle myosin (NM) has a central role in cytokinesis, migration and adhesion.
Objective: We aimed to explore the association of EMT and metastasis with TGF-β1 through regulation of non-muscle myosin II-A (NMII-A) and its interaction with Hexosamine Biosynthesis Pathway (HBP).
Method: Protein expression changes were assessed by western blotting and immunofluorescent staining while transcription level changes were assessed by qRT-PCR. EMT was assessed by phenotypic analysis, wound healing, proliferation and transwell migration assay in vitro while in vivo studies were conducted in BALB/c nude mice for lung orthotopic and tail vein metastasis models.
Results: We demonstrated that regulation of JNK/ P38/PI3K by TGF-β1 led to down expression of NMII-A which promoted EMT and lung cancer metastasis. This down expression of NMII-A conversely upregulated the expression of Core 2 N-acetyl Glucosaminyl Transferase mucin type (C2GnT-M) and further facilitated up-regulation and down-regulation of N-acetylglucosaminyltransferase (GnT) -V and -III respectively; moreover, NMII-A K.D cells showed 3 times more tendency to migrate towards brain in vivo.
Conclusion: The study reports a novel pathway through which NMII-A negatively regulates EMT and metastasis via up regulation of C2GnT-M, GnT-V and down expression of GnT-III. These findings of lung cancer may further be required to study other cancer types.
Export Options
About this article
Cite this article as:
TGF-β1 Causes EMT by Regulating N-Acetyl Glucosaminyl Transferases via Downregulation of Non Muscle Myosin II-A through JNK/P38/PI3K Pathway in Lung Cancer, Current Cancer Drug Targets 2018; 18 (2) . https://dx.doi.org/10.2174/1568009617666170807120304
DOI https://dx.doi.org/10.2174/1568009617666170807120304 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Current Cancer Drug Targets Chemoresistance in Non-Small Cell Lung Cancer
Current Medicinal Chemistry - Anti-Cancer Agents The Significance of Ubiquitin Proteasome Pathway in Cancer Development
Recent Patents on Anti-Cancer Drug Discovery Vitamin D and Lung Cancer
Current Respiratory Medicine Reviews Flt3 Receptor Tyrosine Kinase as a Drug Target in Leukemia
Current Pharmaceutical Design An Update on the Systemic Therapy of Malignant Salivary Gland Cancers: Role of Chemotherapy and Molecular Targeted Agents
Current Medicinal Chemistry - Anti-Cancer Agents Sarcoidosis and Sarcoid Reactions in Endometrial Cancer Cases Masquerading Advanced Stage Malignancy
Current Women`s Health Reviews Kinase Inhibitors Targeting Anti-angiogenesis as Anti-cancer Therapies
Current Angiogenesis (Discontinued) Mitochondrial Superoxide Dismutase: A Promising Target for New Anticancer Therapies
Current Medicinal Chemistry Energy Dependent Transport of Xenobiotics and Its Relevance to Multidrug Resistance
Current Cancer Drug Targets Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Current Cancer Drug Targets Transcriptionally Targeted Adenovirus Vectors
Current Gene Therapy DNA Methyltransferases Inhibitors from Natural Sources
Current Topics in Medicinal Chemistry Anti-Cancer Effect of Melatonin via Downregulation of Delta-like Ligand 4 in Estrogen-Responsive Breast Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery ATP Non-Competitive Ser/Thr Kinase Inhibitors as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Novel Function of Beta 2 Glycoprotein I in Angiogenesis
Current Angiogenesis (Discontinued) Development of Cancer Vaccine Targeting WT1 Product which is Expressed in Various Kinds of Malignant Neoplasms
Medicinal Chemistry Reviews - Online (Discontinued) Predicting Efficacy and Toxicity in the Era of Targeted Therapy: Focus on Anti-EGFR and Anti-VEGF Molecules
Current Drug Metabolism Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics
Current Medicinal Chemistry Molecular Signatures of Biomarkers in Cancer Development, Diagn osis, and its Prognostic Accuracy
Current Biomarkers (Discontinued)